000 03951nam a22003255i 4500
999 _c399169
_d399169
001 399169
003 ES-MaUEC
005 20240408102718.0
006 a||||fo|||| 00| 0
007 cr nn 008mamaa
008 230810s2023 sz | o |||| 0|eng d
020 _a9783031284892
024 7 _a10.1007/978-3-031-28489-2
_2doi
040 _aES-MaUEC
_bspa
_cES-MaUEC
_dES-MaUEC
050 4 _aQR360
_b2023 EB
245 0 0 _aBioprocess and Analytics Development for Virus-based Advanced Therapeutics and Medicinal Products (ATMPs)
_cedited by Saurabh Gautam, Abhilash I Chiramel, Roland Pach
250 _a1st ed. 2023.
264 1 _aCham
_bSpringer International Publishing
_c2023
300 _a1 recurso en línea
336 _atexto
_btxt
_2rdacontent
337 _aelectrónico
_bc
_2rdamedia
338 _arecurso electrónico
_bcr
_2rdacarrier
505 0 _aChapter 1: Bioprocessing and analytical development for virus-based therapeutics -- Chapter 2: Viral Vector Upstream Processing and Clarification -- Chapter 3: Upstream processing of viral therapeutics: From host cell expansion to virus production -- Chapter 4: Leveraging virus biology and host genetic conflicts for cell line development and engineering for virus-based therapeutics -- Chapter 5: Overview of Current Downstream Processing for Modern Viral Vectors -- Chapter 6: Filtration Principles and Techniques for Bioprocessing of Viral Vector-Based Therapeutics -- Chapter 7: Chromatographic purification of viruses: State of the art and current trends -- Chapter 8: Purifying Viral Vectors - A Review of Chromatography Solutions -- Chapter 9: Particle analytics - Comparative approaches for analysis of viral vectors -- Chapter 10: Phase-Appropriate Potency Assay Development for AAV-based Gene Therapy Products -- Chapter 11: Quantification of virus infectivity - the key assay for the development of viral therapeutics -- Chapter 12: Product-related impurities in therapeutic virus bioprocessing -- Chapter 13: Process Analytical Technologies (PAT) and Quality by Design (QbD) for bioprocessing of virus-based therapeutics -- Chapter 14: Methods and practical considerations in imaging viral therapeutics -- Chapter 15: Application of NMR Spectroscopy in Viral Assembly Characterization -- Chapter 16: Improved Production Strategies for Oncolytic Measles Viruses as a Therapeutic Cancer Treatment -- Chapter 17: Recent Advancements and Challenges in Recombinant Expression for Commercial Production of Virus Like Particles (VLPs) -- Chapter 18: Oncolytic viruses and viral gene therapy vectors: Principles of safety.
520 _aThis book reviews the knowledge, methods and available techniques in the rapidly advancing field of virus based vaccines and gene therapeutics. It also highlights new innovative tools and interdisciplinary techniques for bioprocess development and analytics of viruses and viral vectors. As such, it provides a timely and highly relevant resource, since current advances in pharmaceutical research have seen the rise of vaccines and advanced therapeutics and medicinal products (ATMPs), that rely on the power of viruses. However, developing bioprocesses and analytics required to create this often called "magic bullet" (i.e. gene therapy) remains an extremely challenging and costly task. This book offers strategies for overcoming hurdles and difficulties within in all the necessary steps of viral vector development - from scalability to purification methods and quality control. The book is intended for researchers working in academia or industry, as well as graduate students pursuing a career in virology.
988 _aSpringer_BiomedLife_2023
650 7 _2embne
_9413113
_aVirología
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-031-28489-2
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942 _2lcc
_cLE
998 _b04/2024
_dz
_ek
_zSI